 | • レポートコード：360iR22NM041 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、237ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本リサーチレポートによると、2021年に332.7億ドルであった世界の抗凝固剤市場規模が、2022年に365.5億ドルになり、2027年まで年平均10.04%で成長して590.7億ドルに達する見通しです。本レポートでは、抗凝固剤の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、投与経路別（注射薬、経口薬）分析、抗凝固剤別（ベトリキサバン、ダビガトラン、エドキサバン/リバロキサバン、エリキス）分析、薬物クラス別（DTI、ファクターXA阻害剤、ヘパリン、ビタミンK拮抗薬）分析、用途別（心房細動＆心筋梗塞、深部静脈血栓症、肺塞栓症、脳卒中）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを整理しています。本書に記載されている企業情報としては、Akebia Therapeutics, Inc.、Aspen Pharmacare Holdings Limited、AstraZeneca PLC、Athenex, Inc.、Baxter Laboratories Pty Ltd.、Bayer AG、C.H. Boehringer Sohn AG＆Ko. KG、Eli Lilly and Company、Johnson＆Johnson、Mylan N.V.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の抗凝固剤市場規模：投与経路別 - 抗凝固剤注射薬の市場規模 - 抗凝固剤経口薬の市場規模 ・世界の抗凝固剤市場規模：抗凝固剤別 - ベトリキサバンの市場規模 - ダビガトランの市場規模 - エドキサバン/リバロキサバンの市場規模 - エリキスの市場規模 ・世界の抗凝固剤市場規模：薬物クラス別 - DTI（直接トロンビン阻害剤）の市場規模 - ファクターXA阻害剤の市場規模 - ヘパリンの市場規模 - ビタミンK拮抗薬の市場規模 ・世界の抗凝固剤市場規模：用途別 - 心房細動＆心筋梗塞における市場規模 - 深部静脈血栓症における市場規模 - 肺塞栓症における市場規模 - 脳卒中における市場規模 ・世界の抗凝固剤市場規模：地域別 - 南北アメリカの抗凝固剤市場規模 アメリカの抗凝固剤市場規模 カナダの抗凝固剤市場規模 ブラジルの抗凝固剤市場規模 … - アジア太平洋の抗凝固剤市場規模 日本の抗凝固剤市場規模 中国の抗凝固剤市場規模 インドの抗凝固剤市場規模 韓国の抗凝固剤市場規模 台湾の抗凝固剤市場規模 … - ヨーロッパ/中東/アフリカの抗凝固剤市場規模 イギリスの抗凝固剤市場規模 ドイツの抗凝固剤市場規模 フランスの抗凝固剤市場規模 ロシアの抗凝固剤市場規模 … - その他地域の抗凝固剤市場規模 ・競争状況 ・企業情報 |
The Global Anticoagulants Market size was estimated at USD 33.27 billion in 2021 and expected to reach USD 36.55 billion in 2022, and is projected to grow at a CAGR 10.04% to reach USD 59.07 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anticoagulants to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Route of Administration, the market was studied across Injectable Anticoagulants and Oral Anticoagulants.
Based on Anticoagulant Drug, the market was studied across Betrixaban, Dabigatran, Edoxaban / Rivaroxaban, and Eliquis.
Based on Drug Class, the market was studied across DTIs, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
Based on Application, the market was studied across Atrial fibrillation & Heart Attack, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anticoagulants market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anticoagulants Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anticoagulants Market, including Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Baxter Laboratories Pty Ltd., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eli Lilly and Company, Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., Sandoz International GmbH, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Anticoagulants Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anticoagulants Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anticoagulants Market?
4. What is the competitive strategic window for opportunities in the Global Anticoagulants Market?
5. What are the technology trends and regulatory frameworks in the Global Anticoagulants Market?
6. What is the market share of the leading vendors in the Global Anticoagulants Market?
7. What modes and strategic moves are considered suitable for entering the Global Anticoagulants Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
5.1.1.2. Growing number of elderly and obese people
5.1.1.3. Increasing acceptance of novel oral anticoagulants
5.1.2. Restraints
5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
5.1.3. Opportunities
5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
5.1.3.2. Increasing collaboration activities and development of generic drugs
5.1.4. Challenges
5.1.4.1. Potential risk associated with the side-effects and complications associated with the usage of oral anticoagulants
5.2. Cumulative Impact of COVID-19
6. Anticoagulants Market, by Route of Administration
6.1. Introduction
6.2. Injectable Anticoagulants
6.3. Oral Anticoagulants
7. Anticoagulants Market, by Anticoagulant Drug
7.1. Introduction
7.2. Betrixaban
7.3. Dabigatran
7.4. Edoxaban / Rivaroxaban
7.5. Eliquis
8. Anticoagulants Market, by Drug Class
8.1. Introduction
8.2. DTIs
8.3. Factor XA Inhibitors
8.4. Heparin
8.5. Vitamin K Antagonists
9. Anticoagulants Market, by Application
9.1. Introduction
9.2. Atrial fibrillation & Heart Attack
9.3. Deep Vein Thrombosis
9.4. Pulmonary Embolism
9.5. Stroke
10. Americas Anticoagulants Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Anticoagulants Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Anticoagulants Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Akebia Therapeutics, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Aspen Pharmacare Holdings Limited
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. AstraZeneca PLC
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Athenex, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Baxter Laboratories Pty Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bayer AG
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. C.H. Boehringer Sohn AG & Ko. KG
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Eli Lilly and Company
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Johnson & Johnson
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Mylan N.V.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Novartis AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Pfizer Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Sandoz International GmbH
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Sanofi S.A.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Teva Pharmaceutical Industries Ltd.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing